Brief: Acurx Pharmaceuticals Announces Closing Of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: Acurx Pharmaceuticals Announces $2.5 Mln Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: Acurx Receives Positive Regulatory Guidance From EMA For Ibezapolstat Phase 3 Program For CDI
Brief: FDA Provides Positive Feedback On Acurx's CMC Plan For Phase 3
Trump's crypto advocacy steers businesses away from traditional treasury assets
Brief: Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset
Acurx Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Acurx Pharmaceuticals Reports Q3 2024 Results And Provides Business Update
Acurx Pharmaceuticals Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Acurx Announces Additional Ibezapolstat Ph2b Results In Cdi As Well As Anthrax Susceptibility To Acx-375 Analogues
Brief: Acurx Announces Results Of Its Pioneering Research With Ibezapolstat
Acurx Pharmaceuticals Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: USPTO Grants Acurx Pharmaceuticals New Patent For Ibezapolstat To Treat CDI
Acurx Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Acurx Pharmaceuticals Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Acurx Pharmaceuticals Files For Common Stock Offering Size Not Disclosed - SEC Filing
Acurx Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Acurx Pharmaceuticals Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Acurx Says European Medicines Agency Granted SME Designation For Ibezapolstat EU Development